Banlangen is out of stock in many drugstores

According to the news this afternoon, as of 17 PM, Banlangen has been sold out of stock in Jingdong Baiyunshan flagship store, tmall official store and Ali health pharmacy.
According to the Guangzhou Daily, on October 13, the Fourth Board of directors of the Guangdong Macao Joint Research Center for new respiratory pathogens, Baiyunshan Banlangen Macao transformation seminar and cooperation signing ceremony were held in Guangzhou. At the meeting, Zhong Nanshan revealed that his research team carried out a series of in vitro studies and found that Baiyunshan compound Banlangen Granules were effective on new coronavirus. He said that there was a basis for what he said and would not talk nonsense. After more than ten years of joint research, Radix Isatidis has the pharmacological effects of inhibiting virus invasion and regulating inflammation.
Academician Zhong Nanshan said novel coronavirus reported that since the outbreak of the new crown, the research team attached great importance to the study of the anti crown virus of the south medicine, combined with the useful experience of clinical practice, and worked with Guangyao group to carry out in vitro screening of the new type of coronavirus in 16 Chinese patent medicines of 10 enterprises. It was found that the Fufang Banlangen Keli Baiyun Mountain had the inhibitory effect in vitro. The novel coronavirus in Guangdong is being injected into new research and clinical application.
Stimulated by good news, Baiyunshan, A-share listed company, rose to 34.18 yuan / share today, with a total market value of 55.57 billion yuan.
According to Tianyan survey, Baiyunshan’s main business is the research and development, manufacturing and sales of Chinese and Western patent medicines, chemical raw materials, natural drugs, biological medicine and chemical API intermediates; wholesale, retail and import and export of Western medicine, traditional Chinese medicine and medical equipment; research and development, production and sales of large health products; investment in health industry such as medical services, health management, health care and pension.
Guangzhou state owned assets supervision and Administration Commission holds 45.04% of the shares of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., which is the controlling shareholder of Baiyunshan.